Triamcinolone acetonide injectable suspension - Alcon

Drug Profile

Triamcinolone acetonide injectable suspension - Alcon

Alternative Names: Triesence

Latest Information Update: 29 Jun 2016

Price : $50

At a glance

  • Originator Alcon
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Eye disorders; Ocular inflammation

Most Recent Events

  • 26 Jun 2016 Novartis Pharmaceuticals and The Chinese University of Hong Kong plan a prospective clinical trial for Wet age-related macular degeneration (Combination therapy) in China (Intravitreous) (ChiCTR-ICR15006619)
  • 15 Mar 2016 Biomarkers information updated
  • 20 Apr 2015 No recent reports on development identified - Registered for Eye disorders (Diagnosis) in Germany, Belgium, Finland, France, Greece, Italy, Luxembourg, Netherlands, Spain, Sweden and United Kingdom (Intraocular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top